Tazeen Ahmad is a Managing Director in US Equity Research covering small and mid-cap Biotechnology. She joined the firm in 2009 as an associate on the large-cap pharmaceuticals team and transitioned to biotech in 2010. She assumed the role of senior SMID Biotech analyst in 2015. She has been ranked every year since 2017 in the Institutional Investor All-America Research Poll for Small and Mid-Cap Biotechnology, most recently in the #2 position in the 2020 poll. Previously, she was an associate at Citigroup on the large-cap pharma team. She has a bachelor’s degree in biology from Harvard University and is based in New York. For more information about any awards cited, visit https://rsch.baml.com/awards.